Literature DB >> 32495316

Response to Dr. Mahan Regarding Key Points to Consider When Evaluating Andexxa for Formulary Addition.

Harry Peled1, Nhu Quyen Dau2, Helen Lau3.   

Abstract

Year:  2020        PMID： 32495316     DOI： 10.1007/s12028-020-01007-0

Source DB:  PubMed          Journal:  Neurocrit Care        ISSN： 1541-6933            Impact factor:   3.210


× No keyword cloud information.
  4 in total

Review 1.  Anticoagulation reversal for intracranial hemorrhage in the era of the direct oral anticoagulants.

Authors:  Micheal Strein; Scott May; Gretchen M Brophy
Journal:  Curr Opin Crit Care       Date:  2020-04       Impact factor: 3.687

2.  Request for an Andexxa Value Analysis.

Authors:  Ellen Yin; Karen J McConnell
Journal:  Ann Pharmacother       Date:  2020-01-23       Impact factor: 3.154

3.  Evaluation of andexanet alfa and four-factor prothrombin complex concentrate (4F-PCC) for reversal of rivaroxaban- and apixaban-associated intracranial hemorrhages.

Authors:  Megan E Barra; Alvin S Das; Bryan D Hayes; Eric S Rosenthal; Rachel P Rosovsky; Lanting Fuh; Aman B Patel; Joshua N Goldstein; Russel J Roberts
Journal:  J Thromb Haemost       Date:  2020-05-12       Impact factor: 5.824

4.  Comparison of Low- Versus High-Dose Four-Factor Prothrombin Complex Concentrate (4F-PCC) for Factor Xa Inhibitor-Associated Bleeding: A Retrospective Study.

Authors:  H Andrew Wilsey; Abby M Bailey; Aric Schadler; George A Davis; Melissa Nestor; Komal Pandya
Journal:  J Intensive Care Med       Date:  2020-04-03       Impact factor: 3.510
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.